Helping Affected Groups Fight the Opioid Epidemic

Millions of Americans have been hurt by dangerous highly addictive prescription opioids. The Bramzon Law Firm PLLC expert legal team is fighting for justice on behalf of individuals, municipalities, Native American tribes, and other minority groups. Contact us today, we can help.

I agree to the Disclaimer, Privacy Policy and Site Terms of Use.

Helping Victims Groups Fight the Opioid Epidemic.

Millions of Americans have been hurt by dangerous highly addictive prescription opioids. The Bramzon Law Firm PLLC expert legal team is fighting for justice on behalf of municipalities, Native American tribes, and other minority groups. Contact us today, we can help.

I agree to the Disclaimer, Privacy Policy and Site Terms of Use.

The $35 million settlement.


Mallinckrodt Pharmaceuticals and The Justice Department concluded to a $35 million settlement that resolved allegations that Mallinckrodt did not report a very large quantity of oxycodone. The extremely addictive pills were found on the black market in Florida, where they fueled the deadly opioid epidemic.

The agreement is the first with a major manufacturer of the opioids that have sparked a crisis of overdoses and addictions across the country. The Justice Department said the deal establishes “groundbreaking” new standards that require the company to track its drugs as they flow through the supply chain to consumers in an effort to control the epidemic. You can read the full story here.

Today, many victims have filed lawsuits against physicians and drug manufacturers for failing to state the addictiveness of the pills. If you or a loved one are addicted to prescription painkillers, simply contact us today for legal consultation. You may be eligible for financial compensation for your pain.

$150M

MCKESSON CORP.


In January 2017, America’s largest drug distributor—McKesson Corp.—agreed to pay $150 million to the U.S. government to settle Justice Department charges that it failed to detect and report suspicious opioid orders. This was the largest such fine in history.

$44M

CARDINAL HEALTH


In January 2017, Cardinal Health agreed to pay $44 million to three states—Florida, Maryland, and New York—to settle charges that it failed to report and rein in suspicious opioid orders in these states.

$620+M

PURDUE PHARMA


In May 2007, Purdue Pharma agreed to pay at least $600 million in fines after pleading guilty to understating the addictiveness of OxyContin. Purdue had marketed OxyContin as a “reduced-risk” narcotic from its FDA approval in 1995 until 2001 (when it dropped that label).

$24M

PURDUE PHARMA


In December 2015, Purdue Pharma agreed to pay $24 million to the state of Kentucky to settle charges that it understated the addictiveness of OxyContin. State Attorney General Jack Conway said that the money would go to addiction prevention and rehabilitation programs.

$11.75M

COSTCO


In January 2017, Costco agreed to pay $11.75 million to the U.S. government to settle Justice Department charges that the company unlawfully filled prescriptions and failed to maintain accurate records with regard to prescription drugs.

$13.25M

MCKESSON CORP.


In May 2008, McKesson Corp. agreed to pay $13.25 million to state attorney offices in Florida, Maryland, Colorado, Texas, Utah, and California to settle civil charges that three McKesson facilities failed to report suspicious orders of hydrocodone and alprazolam, particularly those placed online and given to customers without prescriptions.

ALARMING INCREASE

The total number of drug-related ED visits increased 81 percent from 2004 (2.5 million) to 2009 (4.6 million). ED visits involving nonmedical use of pharmaceuticals increased 98.4 percent over the same period, from 627,291 visits to 1,244,679.

LARGEST INCREASES

The largest pharmaceutical increases were observed for oxycodone products (242.2 percent increase), alprazolam (148.3 percent increase), and hydrocodone products (124.5 percent). Among ED visits involving illicit drugs, only those involving ecstasy increased more than 100 percent from 2004 to 2009 (123.2 percent increase).

AGE RANGES

For patients aged 20 or younger, ED visits resulting from nonmedical use of pharmaceuticals increased 45.4 percent between 2004 and 2009 (116,644 and 169,589 visits, respectively). Among patients aged 21 or older, there was an increase of 111.0 percent.

MORE ALARMING RATES

ED visits involving adverse reactions to pharmaceuticals increased 82.9 percent between 2005 and 2009, from 1,250,377 visits to 2,287,273. The majority of adverse reaction visits were made by patients 21 or older, particularly among patients 65 or older; the rate increased 89.2 percent from 2005 to 2009 among this age group.

Opioid-Legal-Lonny

TAKE ACTION TODAY

Put our firm's litigation experience to work for you!

I agree to the Disclaimer, Privacy Policy and Site Terms of Use.

TAKE ACTION TODAY

Put our firm's litigation experience to work for you!

I agree to the Disclaimer, Privacy Policy and Site Terms of Use.

Opioid-Legal-Lonny

The Bramzon Law Firm PLLC legal team has helped thousands of clients in the pursuit of justice against big pharmaceutical and medical device corporations. Our preeminent trial team infuses victory in every aspect of fighting for our clients.

The Bramzon Law Firm PLLC legal team has helped thousands of clients in the pursuit of justice against big pharmaceutical and medical device corporations. Our preeminent trial team infuses victory in every aspect of fighting for our clients.

Don’t Delay, Call Today: 855-982-1787

WASHINGTON DC

1200 Pennsylvania Avenue NW
Suite 7601-20045
Washington, DC 20044
map + directions


(855) 982-1787

WASHINGTON DC

1200 Pennsylvania Avenue NW
Ste. 7601-20045
Washington, DC 20044
Fax: (202) 335-0330
map + directions